What is Tesamorelin?
Tesamorelin functions similarly to growth hormone-releasing hormone (GHRH) in the body. Growth hormone (GH) is stimulated by binding to GHRH receptors in the anterior pituitary gland. Increased lipolysis in visceral adipose tissue is one of the metabolic outcomes of this GH rise (1). Researchers have discovered that this technique is especially helpful for lowering extra abdominal fat in HIV-positive individuals with lipodystrophy, a disorder marked by aberrant fat distribution (2). Insulin-like growth factor 1 (IGF-1) levels are also raised by the increased GH release. IGF-1 supports the targeted decrease of fat storage by enhancing fat metabolism (3).
According to clinical research, tesamorelin’s capacity to control these processes may enhance metabolic parameters including liver fat content and glucose metabolism in addition to helping with fat reduction. For the treatment of some metabolic disorders, this makes it an essential therapeutic alternative (4).
Amino Acids Sequence: trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn- Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-Gln- Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.77 g/mol
Buy Tesamorelin Greece for research purposes from PharmaGrade.Store today!
Potential Benefits of Tesamorelin Greece
Scientific studies have suggested that Tesamorelin Peptide could have the following potential benefits:
Weight loss: Reduces excess abdominal fat in patients with human immunodeficiency virus with lipodystrophy, improving their body fat distribution and health (2). Fat Burning: Promotes targeted fat reduction by increasing the breakdown of visceral fat through growth hormone secretion (1). Liver health: Lowers the risk of non-alcoholic fatty liver disease (NAFLD) by increasing the amount of fat in the liver (4). Improved metabolism: This has a positive impact on the metabolism of glucose and may help control blood sugar levels. Additionally, tesamorelin increases levels of insulin-like growth factor-1 (IGF-1), which improves metabolic function in general (3).
Research on Tesamorelin Greece
Tesamorelin, a synthetic growth hormone-releasing factor analog, stimulates natural growth hormone production by activating GHRH receptors in the pituitary gland (5). Its primary use has been to reduce visceral fat in HIV patients with lipodystrophy, with studies showing a significant decrease of up to 18% in visceral adipose tissue without adverse effects on glucose metabolism (6). Long-term use also enhances body image and metabolic profiles.
Recent studies demonstrate Tesamorelin’s effectiveness in improving cognitive function, including potential roles in neuroprotection and memory enhancement (7). Tesamorelin is a promising tool for broader therapeutic applications because of its impact on metabolic health, including improved insulin sensitivity and cholesterol management.
What Customers Ask about Tesamorelin Greece
Tesamorelin is not typically used to treat general growth hormone deficiency. Instead, it is primarily prescribed for reducing excess visceral obesity in HIV-infected patients with lipodystrophy. It works by stimulating the release of growth hormone, which helps target and reduce abdominal fat. While it does influence overall growth hormone levels, its use is more specialized and not a standard treatment for broader growth hormone deficiency conditions.
Yes, Tesamorelin is an FDA approved medication for HIV-associated lipodystrophy. It is used to reduce excess abdominal fat in patients with HIV who experience this condition as a side effect of antiretroviral therapy. Tesamorelin works by stimulating the release of growth hormone, which helps to reduce visceral fat. However, it is not a treatment for HIV itself, but rather for managing a specific complication associated with the condition. Always consult a healthcare provider for personalized medical advice.
Tesamorelin can affect blood sugar levels because it stimulates the release of growth hormone, which plays a role in glucose metabolism. Clinical studies have shown that some individuals experience small increases in fasting blood glucose or HbA1c during treatment, although these changes are generally modest. Tesamorelin has also been investigated for its ability to reduce visceral abdominal fat, which may have positive effects on metabolic health in certain populations. Overall, its impact on blood sugar appears to vary between individuals, and further research continues to explore its long-term metabolic effects. Anyone with diabetes or impaired glucose tolerance should be appropriately monitored under medical supervision if prescribed Tesamorelin.
Tesamorelin is designed to stimulate growth hormone release by acting on growth hormone-releasing hormone (GHRH) receptors and does not directly stimulate cortisol production. Clinical studies have generally found that Tesamorelin has little to no significant effect on cortisol levels in most individuals. However, because the endocrine system is highly interconnected, hormonal responses can vary between individuals. Current research suggests that Tesamorelin primarily influences the growth hormone/IGF-1 axis rather than the hypothalamic-pituitary-adrenal (HPA) axis responsible for regulating cortisol.
Tesamorelin is not classified as a weight loss peptide. It is a synthetic GHRH that stimulates the body’s natural production of growth hormone. Tesamorelin is approved in some countries for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, rather than for general weight management.
Greece Research has shown that Tesamorelin can reduce visceral fat—the fat stored around internal organs—which may improve body composition in specific populations. However, it is not intended to produce overall weight loss, and changes in total body weight are often modest.
Further Reading
References:
(1) Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017 Oct 23;31(16):2253-2259.
(2) Esteban Martínez, Disorders of fat partitioning in treated HIV–infection, Best Practice & Research Clinical Endocrinology & Metabolism, Volume 25, Issue 3, 2011, Pages 415-427.
(3) Al-Samerria S, Radovick S. Exploring the Therapeutic Potential of Targeting GH and IGF-1 in the Management of Obesity: Insights from the Interplay between These Hormones and Metabolism. Int J Mol Sci. 2023 May 31;24(11):9556.
(4) Stergios A. Polyzos, Nikolaos Perakakis, Christos S. Mantzoros, Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement, Metabolism, Volume 96, 2019, Pages 66-82.
(5) Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009 Mar;18(3):303-10.
(6) Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22.
(7) Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013 Jul;70(7):883-90.
Useful Links
Shop Research Peptides with PharmaGrade.Store View an Introduction to Peptides Discover more Frequently Asked Questions about Peptides Learn more about Peptide Bonds Shop Laboratory Consumables View Carefully Selected Peptide Stacks
Buy Tesamorelin Greece Today from PharmaGrade.Store
Laboratory Tested Peptides
Shipping Worldwide
Great Customer Service
All Orders Tracked
Highest Quality 98%+ Purity
ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE FOR EDUCATIONAL PURPOSES ONLY
DISCLAIMER: All products sold by PharmaGrade.Store are for research and laboratory use only. These products are not designed for use or consumption by humans or animals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such. By purchasing from our Website the buyer accepts and acknowledges the risks involved with handling of these products. All articles and product information provided on this Website are for informational and educational purposes only. Handling and use of these products should be restricted to suitably qualified professionals